Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. Presenting below are its Q1 FY26 earnings results.
Q1 FY26 Earnings Results
-
Consolidated Revenue: ₹3,570.35 crores, up 24.4% YoY (Q1 FY25: ₹2,867.85 crores).
-
Profit After Tax (PAT): ₹445 crores, down 18% YoY (Q1 FY25: ₹536.49 crores).
-
EBITDA: ₹850 crores, EBITDA margin at 23.8%, up 20 basis points YoY.
-
Profit Before Tax (PBT): ₹926.65 crores, up from ₹770.96 crores YoY.
-
Standalone Revenue: ₹2,541.36 crores, up 5.3% YoY, PAT ₹412.76 crores, down 13.4% YoY.
-
Earnings Per Share (EPS): ₹10.62, down 20.69% YoY (Q1 FY25: ₹13.40).
-
Domestic Business Revenue: ₹3,101 crores, up 18.9% YoY, driven by steady base business and Bharat Serums and Vaccines (BSV) consolidation.
-
Export & Consumer Healthcare Business: ₹469 crores (up 81.1% YoY), ₹237 crores (up 15% YoY) respectively.
-
Increase in Costs: Higher employee expenses, increased R&D investments, and raw material costs impacted profit margins.
Management Commentary & Strategic Highlights
-
The decline in net profit was attributed to increased input and operational costs alongside investments in growth initiatives like R&D and talent.
-
Strong growth in chronic therapies, consumer healthcare segment, and consolidation of BSV contributed to overall revenue growth.
-
Management expressed confidence in healthy performance continuation backed by niche specialty portfolio and market expansion.
-
The board declared an interim dividend of ₹1 per share to reward shareholders on the company’s 30th anniversary.
Q4 FY25 Earnings Results
-
Revenue: ₹3,079 crores.
-
Profit After Tax: ₹425 crores.
-
EBITDA Margin: Approximately 24%.
-
EPS: ₹10.2.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.